Detalhe da pesquisa
1.
Cancer immunotherapy responses persist after lymph node resection.
bioRxiv
; 2024 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37781599
2.
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.
JAAD Int
; 15: 105-114, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38500872
3.
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
Eur J Cancer
; 194: 113354, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37827067
4.
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
EClinicalMedicine
; 65: 102290, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37965433
5.
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
EClinicalMedicine
; 71: 102564, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38572079